GlaxoSmithKline (GSK) and Innoviva have initiated a Phase III Captain study of a triple combination therapy consisting of fluticasone furoate / umeclidinium / vilanterol (FF/UMEC/VI) compared to dual combination therapy of Relvar / Breo (FF/VI) to treat asthma.

Fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta-adrenergic agonist (LABA), all three of which are delivered through GSK’s Ellipta dry powder inhaler.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Innoviva CEO Mike Aguiar said: “Closed triple therapy may provide a new once-a-day treatment option for asthma patients not adequately controlled by existing therapy.

“If successful, this would further expand the portfolio of respiratory therapy products delivered via the Ellipta inhaler for the treatment of asthma and COPD.”

"If successful, this would further expand the portfolio of respiratory therapy products delivered via the Ellipta inhaler for the treatment of asthma and COPD."

The Phase III Clinical study of Asthma Patients receiving Triple therapy through A single Inhaler (CAPTAIN) is being conducted as a randomised, double-blind, active controlled, six-arm parallel group, global multicentre study to evaluate FF/UMEC/VI against FF/VI for treating patients whose asthma is inadequately controlled despite treatment with maintenance asthma medication.

See Also:

The study is planning to enrol 2,250 patients, out of which 375 will be randomly divided into six treatment arms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is primarily focused on determining the baseline change in trough Forced Expiratory volume in one second (FEV1) after completing 24 weeks of treatment.

The secondary endpoint of the trial is to determine the rate of moderate / severe asthma exacerbations on an annual basis. Other secondary endpoints are to evaluate quality of life and symptom control as a result of the triple combination therapy.